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Undecylenic acid is an unsaturated fatty acid that has been incorporated in topical
medications for its anti-fungal effects (1, 2, 3,4, 5); and more recently has been given orally.
Penman (6) reported excellent success in the use of undecylenic acid by the oral route in
psoriasis and in atopic dermatitis.
Because of the lack of effective systemic measures for these diseases, dermatologists
have long been studying the value of new approaches. Among these, undecylenic acid was
given a trial in a series of patients in the private practice of Dr. Marion B. Sulzberger.
The purpose of this paper is to report upon 40 cases of dermatoses treated with unde-
cylenic acid administered orally from June, 1948 to March, 1949.
SUMMARY OF CASES STUDIED
Thirty cases of psoriasis, 3 cases of atopic dermatitis, 4 of seborrheie dermatitis and 3
cases of scaly and erythematous dermatoses in which the diagnosis was not conclusively
established, were studied.
Patients ranged in age from 8 to 69 years, and there were 21 men and 19 women. The
dermatoses had been present for different lengths of time. The psoriatics had been affected
from 4 months to about 40 years, but only 2 had had the disease for less than 1 year. One
young woman had had psoriasis since the age of 9 months.
Those with atopic dermatitis had been ill from 8 months to 11 years.
One to 10 years was the duration of seborrheic dermatitis in the cases studied.
DOSAGE AND EFFECTS
Undecylenic acid was supplied as a 0.44 gm. sealed perle, and as 0.2, 0.5 and 0.8 gram
capsules.' The dosage schedule ranged from 0.6 gm. per day to 19.8 gm. (45 X 0.44 gin.)
daily. The final schedule arrived at was: 0.44 gm. X 5 three times daily for 2 days; then
0.44 gm. X 10 three times daily for 2 days; and 0.44 gm. X 15 perles three times a day there-
after.
No serious contraindication to the use of the unsaturated fatty acid was apparent.
However, because of the frequency of side effects—nausea, vomiting, and diarrhea—there
may be hesitation to use undecylenic acid where there is gastrointestinal disease. Salts,
esters or coatings may obviate or reduce gastrointestinal side effects.
The length of the course of treatment was under 3 weeks in of the cases; from 3 to 5
weeks in another quarter; and in 42% (17 cases) ranged from 6 weeks to over 7 months.
TOTAL GROUP
Of the 40 patients treated, 15 showed aggravation of the eruption or no effect at all; and
5 showed indefinite reactions; i.e., no evaluation was possible. Twenty showed fair or good
improvement. However, these improvements could not be attributed with certainty to
undecylenic acid since in practically every one of the improved cases some concomitant
local therapy had to be used.
'We are greatly indebted to Wallace Laboratories and then to Decyl Laboratories, New
Brunswick, N. J., for supplying the material used.
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PSORIASIS
Response to undecylenic acid in the thirty cases of psoriasis seemed at best to be inconclu-
sive. Five cases showed good improvement (marked decrease of abnormal skin findings)
and four became worse under treatment. Nine cases improved moderately (i.e., less symp-
toms and slight decrease in intensity of dermatosis); eight cases were unchanged. Four
persons could not be rated for therapeutic effect.
ATOPIC DERMATITIS
Of the three cases of atopic dermatitis, one was unchanged, one got slightly better, and
one did very well.
SEBOERHEIC DERMATITIS
Undecylenic acid seemed most promising in seborrheic dermatitis. In four trials, only
one produced no change, while in the other three there was moderate to marked improve-
ment.
INFLUENCE OF AGE
The therapeutic response according to age group seemed too random to warrant com-
ment. The only interesting observation is the frequency of adverse change in the dermatoses
of persons over 60 years. Of 7 patients between 60 to 70 years old, 3 became worse while
taking undecylenic acid.
SIDE EFFECTS
Side effects occurred consistently in 35% (14) of the series. Twelve reactions involved
the gastrointestinal tract (nausea, eructations, flatulence, vomiting and diarrhea). One
patient reported also fever, headache and increased pruritus. Another reported dizziness,
and still another, urticaria.
COMMENTS
After a survey of forty cases, little of a positive nature can be said about the practical
usefulness of undecylenic acid by mouth. While 50% of cases showed some improvement
during the months in which the medication was given, there were adverse or no changes in
35%, and equivocal results in the remainder. Whether the improvement will be maintained
in the improved cases is uncertain.
In at least one case, improvement was only temporary, and there was a relapse with de-
velopment of many new psoriatic plaques while the high undecylenic acid dosage was main-
tained.
Over of the patients (35%) had mild to moderate side effects, that affected the gastro-
intestinal tract chiefly.
There is of course question whether the therapeutic results demonstrated are much
different from those to be expected by chance fluctuations. However, because of its possibly
immense practical and theoretical significance in a disease as common and as mysterious
as psoriasis, any approach which may effect a cure in even a small proportion of cases should
not be abandoned without thorough and careful study. More data are required.
SUMMARY
1. Forty cases of psoriasis, atopic dermatitis, seborrheic dermatitis, and other derma-
toses were treated with undecylenic acid.
2. Half the cases showed fair to good improvement within a period of several months
during which the medication was given. It is not known whether improvement was due to
the acid or to other measures, or if it was maintained.
3. In of the cases, there were side reactions—chiefly nausea, vomiting and diarrhea.
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4. The reported series is still too small to permit a statistical evaluation of oral unde-
cylenic acid and studies with this material must be continued.
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